iF488 Anti-Human CD279 (PD1) Antibody

Product Details


Clone279AM1
ApplicationFlow Cytometry
ReactivityHuman
FormatiF488
Target NameCD279, PD1, PD-1
IsotypeMouse IgG1
Antibody TypeMonoclonal
Regulatory StatusRUO
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein ConcentrationSupplied at a lot-specific concentration.
Storage&HandlingThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended UsageFor flow cytometric staining, it is recommended to use 5 uL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application.
Excitation LaserBlue Laser (488 nm)
RRIDAB_3738613
See All FormatsClone 279AM1

Background Information


CD279, also known as Programmed cell death 1 (PD-1), cell surface receptor which binds to PD-L1 and PD-L2 ligands; functions as immune checkpoint with important role in down regulating immune system by preventing T-cell activation. Targeted by Nivolumab, Pembrolizumab and other monoclonal antibodies in a new class of cancer drugs. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. The interaction with CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Data Sheets


iF488 Anti-Human CD279 (PD1) Antibody TDS

Related Protocols


Flow Cytometry Protocol

Related Products


Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2

Biotin Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2

Anti-Human PD-L1 (Atezolizumab Biosimilar), Clone Atezolizuma

Anti-Human PD-L1 (Avelumab Biosimilar), Clone Avelumab

Human PD1 (CD279) Protein (C-His-Avi)

Biotin Human PD1 (CD279) Protein (C-His-Avi)

Human PD1 (CD279) Protein (C-His)

Anti-Human PD-1 (Camrelizumab Biosimilar), Clone Camrelizumab

Anti-Human PD-1 (Cemiplimab Biosimilar), Clone Cemiplimab

Anti-Human PD-1 (Nivolumab Biosimilar), Clone Nivolumab


Have a product or application question? Consult our FAQs or contact us.